Company Orthocell Limited

Equities

OCC

AU000000OCC6

Advanced Medical Equipment & Technology

Market Closed - Australian S.E. Other stock markets 10:29:44 19/01/2026 am IST			5-day change	1st Jan Change
1.000 ^AUD	0.00%		-5.66%	-7.83%

16/01	Orthocell Finalizes Agreement With Biotechnology Company	MT
16/01	Orthocell finalises strategic investment in Marine Biomedica	RE

Business description: Orthocell Limited

Orthocell Limited is an Australia-based regenerative medicine company. The Company is focused on regenerating mobility for patients by developing products for the repair of a variety of bone and soft tissue injuries. Its portfolio of products includes Striate+, Remplir, and OrthoACI. Striate+ is a sterile, resorbable collagen membrane used for guided bone and tissue regeneration in dental applications. Remplir is a collagen scaffold used in peripheral nerve repair. OrthoACI or autologous chondrocyte implantation is used for the treatment of articular cartilage defects in the knee and ankle. OrthoACI uses the patientâs own healthy cartilage cells called chondrocytes to assist the regeneration of damaged cartilage. The Company is engaged in the development of its tendon cell therapy in the United States. Its autologous tendon therapy is an advanced injectable cellular therapy for the treatment of chronic tendon injuries.

Sales by Activity: Orthocell Limited

Fiscal Period: June	2021 (AUD)	2022 (AUD)	2023 (AUD)	2024 (AUD)	2025 (AUD)
Regenerative Medicine Industry	10.18L	15.32L	42.43L	53.15L	75.51L

See all business segments

Geographical breakdown of sales: Orthocell Limited

Fiscal Period: June	2021 (AUD)	2022 (AUD)	2023 (AUD)	2024 (AUD)	2025 (AUD)
Australia	10.18L	15.32L	42.43L	53.15L	75.51L

See all geographic segments

Executive Committee: Orthocell Limited

Manager	Title	Age	Since
Ming Hao Zheng CTO	Chief Tech/Sci/R&D Officer	-	21/03/2006
Paul Anderson CEO	Chief Executive Officer	60	21/03/2006
Tony Macintyre CTO	Chief Tech/Sci/R&D Officer	-	01/04/2024
Alex McHenry COO	Chief Operating Officer	-	01/01/2016
Adam Wood PRN	Corporate Officer/Principal	-	02/07/2025

See ORTHOCELL LIMITED governance

Composition of the Board of Directors: Orthocell Limited

Director	Title	Age	Since
Paul Anderson BRD	Director/Board Member	60	21/03/2006
Ravi Thadhani BRD	Director/Board Member	60	08/03/2023
John van der Wielen CHM	Chairman	-	01/06/2023
Fiona Wood BRD	Director/Board Member	-	01/11/2023
Michael McNulty BRD	Director/Board Member	-	01/09/2025

Composition of the Board of Directors

Shareholders: Orthocell Limited

Name	Equities	%	Valuation
Paul Anderson 2.72 %	73,78,900	2.72 %	5 M $
Ming Hao Zheng 2.607 %	70,73,975	2.607 %	5 M $
Qi Xiao Zhou 2.21 %	59,96,241	2.21 %	4 M $
Jia Xu 1.764 %	47,85,445	1.764 %	3 M $
Wyllie Group Pty Ltd. 1.701 %	46,14,992	1.701 %	3 M $

List of ORTHOCELL LIMITED shareholders

Company details: Orthocell Limited

Orthocell Ltd.

Murdoch University

6150, Murdoch

http://orthocell.com

Other Advanced Medical Equipment & Technology

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
ORTHOCELL LIMITED	0.00%	-5.66%	-21.88%	+135.29%	18Cr
THERMO FISHER SCIENTIFIC, INC.	-0.95%	-0.02%	+10.55%	+6.67%	23TCr
INTUITIVE SURGICAL, INC.	-1.17%	-8.74%	-9.73%	+108.70%	19TCr
DANAHER CORPORATION	-1.63%	-1.00%	-0.99%	-12.80%	17TCr
BOSTON SCIENTIFIC CORPORATION	-2.18%	-9.80%	-10.73%	+95.32%	13TCr
SIEMENS HEALTHINEERS AG	-1.07%	-0.45%	-11.20%	-6.05%	5.99TCr
EDWARDS LIFESCIENCES CORPORATION	-0.17%	-0.92%	+20.88%	+7.71%	4.89TCr
AGILENT TECHNOLOGIES, INC.	-3.58%	-5.98%	-5.24%	-9.37%	3.96TCr
RESMED, INC.	-1.20%	+2.02%	+7.42%	+13.99%	3.75TCr
GE HEALTHCARE TECHNOLOGIES INC.	-0.92%	-6.34%	-3.53%	+31.68%	3.72TCr
Average	-1.29%	-3.86%	-2.44%	+37.12%	9.43TCr
Weighted average by Cap.	-1.37%	-3.80%	-0.71%	+35.91%